본문 바로가기
  • Home

A Study about modification of Gejitang that showed on sympton and prescription about Soumin

  • Journal of Sasang Constitution and Immune Medicine
  • Abbr : J Sasang Constitut Med
  • 1999, 11(1), pp.201-220
  • Publisher : The Society of Sasang Constitution and Immune Medicine
  • Research Area : Medicine and Pharmacy > Korean Medicine
  • Received : November 30, 1999
  • Accepted : November 30, 1999
  • Published : November 30, 1999

KIm Jeong-hee 1 Jeong-Mo Song 2

1우석대
2우석대학교

ABSTRACT

We got these results after studying about modification of Gejitang(桂枝湯) that showed on sympton and prescription about Soumin(少陰人). 1. There are totally eleven prescriptions related to Gejitang appeared on Dongyi-Soose-Bowon(東醫壽世保元). Among them, one is prescription of Danguisayoktang(當歸四逆湯) in prescription of Discussion of Cold Induced Disorder(傷寒論) and another is Gejibujatang(桂枝附子湯) in Won-Myung dynasty period(元明時代). There are nine prescriptions in LeeJae-Ma(李濟馬)'s pre-scription and we can see there are many prescriptions used prescriptions related to Gejitang for Mang Yang(亡陽). 2. Pre-scriptions related to Gejitang has seven prescriptions in Extra-disease(表病證), and two prescriptions in Intra-disease(裏病證) which are analyzed as modified prescription from Gejitang. 3. Although 藿香正氣散, 香蘇散, 芎歸香蘇散, 八物君子湯 etc. are not modified prescriptions of Gejitang, We can see that its are brought up to be on the same with alternative remedy of Gejitang in each step of symptoms. 4. Symptoms are exactly classified in Soumin, the prescription which is used in different symptoms of diseases is similar in raw materials. It's because the remedy of Acending and Descending(升降) is used under the same purpose that maintain Yangnan Qi(陽暖之氣). 5. We could realize that Panax gienseng(人蔘), Cinnamomum Cassia(肉桂) and Aconitum Carrnichali(附子) are commonly important to reinforce Yangnan Qi because the more disease got worse, the more patient lost Yangnan Qi on both Extra-disease and Intra-disease in the Soumin's disease.

KEYWORDS

no data found.

Citation status

* References for papers published after 2023 are currently being built.